Cyclica & ATAI Life Sciences form Entheogenix Biosciences for Mental Health Treatment Research

November 18, 2019

New York - Paul Hastings, a leading global law firm, announced today that the firm represented Cyclica Inc., a leading artificial intelligence-powered biotechnology company on the creation of Entheogenix Biosciences, a joint venture with ATAI Life Sciences.

Entheogenix Biosciences is aimed at advancing psychedelic research for the development of better medicines for mental health diseases such as depression, bipolar disorder, and schizophrenia. Current therapies that rely on single-targeted drug interventions often fall short. Through artificial intelligence, computational biophysics, and a data-driven pipeline, Entheogenix’s goal is to design and synthesize new compounds from psychoactive seed small molecule compounds.

“Our vision is to spark a new era of drug discovery centered on a robust computation-centric approach. We are especially passionate about advancing health outcomes for patients suffering with the most complex and prevalent disorders like depression, which is the leading cause of disability worldwide,” said Naheed Kurji, President and CEO of Cyclica. “We’re thrilled to partner with the world-class team at ATAI on this paradigm shifting venture.”

The Paul Hastings team was led by partner Samuel Waxman, and also included associate Joseph Herman.

At Paul Hastings, our purpose is clear—to help our clients and people navigate new paths to growth. With a strong presence throughout Asia, Europe, Latin America, and the U.S., Paul Hastings is recognized as one of the world’s most innovative global law firms.